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variation (90% confi dence interval, –18% 
to +18%), and the interobserver coeffi  cient 
of variation is also fairly high.11 Th us the 
prediction power of troponin T, which in 
a way is a biochemical marker of LV mass, 
may refl ect residual confounding attribut-
able to the fact that LV mass is measured 
imprecisely by echocardiography. In other 
words, adjustment for LV mass might not 
take away the whole eff ect of this factor. 
On the other hand, in biological terms, 
troponin provides information that goes 
beyond LV mass and function, because 
the plasma concentration of this substance 
refl ects myocardial-cell distress. Th us it 
may also be that the good prediction power 
of troponin T depends on the fact that this 
biomarker adds relevant biological infor-
mation (myocardial-cell distress) to that 
provided by echocardiographic measure-
ment of LV mass. As is mentioned above, 
the fact remains that this biomarker, inde-
pendently of the nature of the link between 
plasma troponin and circulatory overload, 
emerges as a most promising prognostic 
factor for this outcome in PD patients. 
Validation of a biomarker is a complex 
process1 that also requires appropriate 
studies testing whether measurement of 
the biomarker is useful in clinical prac-
tice. The United States Food and Drug 
Administration approved the measure-
ment of troponin T in dialysis patients for 
risk stratifi cation. However, a prospective, 
randomized clinical trial testing the value 
of troponin in a clinical decision-making 
context is still needed to solidly estab-
lish the place of this biomarker in eve-
ryday clinical practice in ESRD patients. 
For example, should these patients be 
intensively treated by a pharmacological 
approach, or should they be considered 
for coronary revascularization even in the 
absence of symptoms? Th e study by Wang 
et al.4 off ers an important new piece of 
evidence on the potential usefulness of 
troponin T in asymptomatic PD patients 
and makes even more compelling the case 
for prospectively testing treatment policies 
that incorporate this biomarker in the 
management of these patients.
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Myostatin and insulin-like growth 
factors in uremic sarcopenia: 
the yin and yang in muscle mass 
regulation
RH Mak1 and P Rotwein2
Myostatin and the insulin-like growth factors (IGF-I and -II) play inhibitory 
and stimulatory roles, respectively, in the development and regulation of 
skeletal muscle mass. The findings of Sun et al. in this issue shed light on 
the potential regulation and actions of this yin-and-yang system in uremic 
sarcopenia and the salutary effects of exercise.
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Myostatin (also known as growth/diff eren-
tiation factor-8) is a member of the trans-
forming growth factor-β family that plays 
an essential role in the regulation of skel-
etal muscle mass. Myostatin is expressed 
initially in the myotomal compartment of 
developing somites and continues to be 
expressed in muscle throughout develop-
ment and in adult animals. Mice with a 
targeted disruption of the myostatin gene 
display a marked increase in muscle mass, 
up to three times normal size, as a result of 
a combination of muscle fi ber hyperplasia 
and hypertrophy. Th e myostatin sequence 
has been highly conserved throughout evo-
lution. Remarkably, the human, rat, mouse, 
porcine, turkey, and chicken proteins are 
identical in the biologically active COOH-
terminal portion of the molecule. Th e func-
tion of myostatin as an inhibitor of skeletal 
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muscle growth also appears to be con-
served across species. A frameshift  muta-
tion, caused by an 11-nucleotide deletion in 
the third exon of the gene, which eliminates 
virtually all of the region encoding the 
mature portion of the myostatin molecule, 
has been linked to the ‘double muscling’ 
phenotype in Belgian blue cattle, which is 
characterized by a generalized increase in 
muscle mass. Another apparently sponta-
neous mutation in the myostatin gene in 
a child is also associated with enormous 
muscle hypertrophy.1
In addition to local actions in skeletal 
muscle during development, myostatin 
may have endocrine functions in adult 
animals. Myostatin circulates in a latent 
form that can be activated by acid treat-
ment. Indeed, systemic overexpression of 
myostatin in adult mice induced profound 
muscle and fat loss analogous to that seen 
in human cachexia syndromes. Thus, 
myostatin may act as a muscle ‘chalone,’ a 
term proposed over 30 years ago for a cir-
culating protein that inhibits the growth of 
a particular tissue and thereby maintains 
appropriate tissue mass.2
Insulin-like growth factor-I (IGF-I) and 
IGF-II are essential for embryonic and post-
natal development of skeletal muscle and 
other tissues. Mice engineered to lack IGF-
I or the IGF-I receptor were signifi cantly 
smaller than their control littermates and 
had reduced muscle tissue, whereas trans-
genic mice with targeted overexpression of 
IGF-I to muscle showed increased muscle 
mass.3 Additionally, IGF-II expression has 
been positively associated with skeletal 
muscle development in double-muscled 
cattle and in pig breeds with exceptional 
muscle mass.4 In vitro, IGFs inhibit apop-
tosis and can promote the proliferation and 
diff erentiation of skeletal muscle cells.3 In 
rodents, work overload (WO) has been 
shown to cause muscle hypertrophy by 
activating intracellular signaling path-
ways that are linked to local production 
of IGFs by growth hormone-independent 
mechanisms.5 Th e less severe stimulus of 
repetitive exercise also promotes muscle 
growth, and this adaptive response can be 
enhanced in transgenic mice expressing 
IGF-I in muscle,6 and prevented in mice 
with a dominant-negative form of the 
IGF-I receptor targeted to muscle.7 Th us, 
the benefi cial eff ects of exercise on muscle 
are mediated at least in part through para-
crine actions of local IGF-I.
Cachexia, presenting as sarcopenia 
(disproportionate muscle wasting), is 
reported to have a prevalence of 30%–60% 
in patients with end-stage renal disease and 
contributes to both mortality and morbid-
ity in these individuals. Loss of skeletal 
muscle mass and strength is probably the 
most important factor regulating survival 
in patients with end-stage kidney disease, 
since with severe muscle atrophy critical 
physiological functions are signifi cantly 
impaired. Substantial muscle loss also 
contributes directly to asthenia and to the 
reduction in physical activity and quality 
of life seen in end-stage renal disease. Th e 
molecular mechanisms causing uremic sar-
copenia are not well understood, although 
the etiology is multifactorial and includes 
contributions from infl ammation, ano-
rexia, increased metabolic rate, acidosis, 
and resistance to anabolic hormones such 
as growth hormone and IGF-I.
Sun and colleagues8 (this issue) showed 
that WO, produced by experimental uni-
lateral gastrocnemius tendon ablation, 
corrected uremic sarcopenia. In the atro-
phied uremic muscle, basal myostatin 
mRNA levels were increased signifi cantly 
but were reduced toward normal values 
aft er WO, suggesting a role for myostatin 
in the wasting process. WO led to a rise 
in muscle IGF-I mRNA levels and IGF-I 
protein expression in both uremic and 
pair-fed control rats. On the other hand, 
stimulation of IGF-I expression by growth 
hormone was severely attenuated in ure-
mic rats compared with controls. Th us, 
WO could bypass the growth hormone 
resistance seen in uremia and could restore 
IGF-I expression in muscle in association 
with correction of uremic muscle atrophy. 
In the aggregate, these fi ndings provide 
insight into mechanisms of skeletal muscle 
wasting in uremia by linking it to enhanced 
myostatin expression, and they additionally 
demonstrate that the anabolic response to 
local WO remains intact in uremia, as do 
the molecular pathways promoting work-
induced IGF-I gene and protein expression. 
In addition, the observations of Sun et al.8 
suggest that less severe stimulus of exercise 
also may promote positive energy balance 
in muscle through stimulation of local pro-
duction of IGF-I and inhibited expression 
of myostatin (Figure 1).
Th e signifi cance of the fi ndings of Sun 
and colleagues8 to human renal disease 
is not clear. In a recent study of sedentary 
well-nourished maintenance hemodialysis 
patients, Wang et al.9 showed that myosta-
tin mRNA levels in skeletal muscle were 
similar to values in normal control sub-
jects. Th e diff erences in myostatin gene 
expression noted in uremic rats with sar-
copenia and seen in hemodialysis patients 
in the study by Wang et al. may refl ect the 
fact that the human subjects were well 
nourished and had no clinical evidence 
of muscle wasting. Indeed, nutritional 
parameters such as body mass index, per-
centage body fat, skin-fold thickness, and 
muscle circumference did not diff er from 
those of healthy controls. Furthermore, 
these patients had normal appetites and 
had little evidence of systemic infl amma-
tion, as indicated by normal C-reactive 
protein concentrations. It is also possible 
that species diff erences are contributing to 
the divergent results. In a previous study, 
myostatin could be detected in the blood 
in mice but not in humans.2
Despite these caveats, the clinical impli-
cations of this study are signifi cant. Exer-
cise in the form of endurance or resistance 
training may suppress muscle myostatin 
expression and may reverse or limit sarco-
penia. In a preliminary report, myostatin 
mRNA levels were decreased aft er pro-
longed endurance exercise training in 
dialysis patients.10 Th us exercise may well 
be an important adjunct therapy in these 
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Figure 1 | Myostatin (–) and IGF-I (+) 
modulation of muscle mass and the effects 
of uremia and exercise.
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individuals. Clinical studies are thus much 
needed to examine the diff erential benefi ts 
of endurance versus resistance training for 
sarcopenia, for infl ammation, and for over-
all mortality and morbidity in patients with 
end-stage renal disease. In addition, further 
investigation into the molecular pathogen-
esis of uremic cachexia and sarcopenia may 
reveal novel therapeutic targets for pre-
venting these potentially life-threatening 
complications.
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Dendritic cells: Not just another 
cell type in the kidney, but a 
complex immune sentinel network
C Kurts1
Dendritic cells (DCs) are crucial for inducing and regulating adaptive 
immunity. These cells also exist in the kidney, where, however, their 
function had been unknown. A study by Soos et al. now demonstrates 
that renal DCs form an intricate cellular network that continuously surveys 
the tubulointerstitium, and reveals a previously unrecognized immune 
sentinel system of the kidney.
Kidney International (2006) 70, 412–414. doi:10.1038/sj.ki.5001613
Dendritic cells (DCs) represent one of 
the most extensively studied topics in 
immunology, because of their central 
role in the induction and regulation of 
adaptive immunity, and because of their 
therapeutic potential for manipulating 
immune responses. Most of our knowl-
edge of their physiology was extrapolated 
from in vitro studies, or from in vivo 
analysis of the secondary lymphatics and 
the skin, where DCs are copious and rela-
tively easily accessible. Yet even so, DCs 
reside in virtually all tissues, including 
the kidney. Despite their obvious poten-
tial to contribute to renal infl ammation, 
these cells have received relatively little 
attention so far. Th is may now change, 
as novel transgenic mouse strains have 
become available that greatly facilitate 
their observation in vivo. Th is issue of 
Kidney International features a study by 
Soos et al. that used such a mouse strain 
to reveal an intricate network of DCs that 
appear to patrol the renal tubulointersti-
tium (Figure 1).1 Th e complexity of this 
network is surprising. Evidently, the DCs 
residing in the kidney form an immuno-
surveillance network whose extent has 
not been fully appreciated yet.
The principal DC function is the 
induction of adaptive immune responses, 
in particular those executed by T cells. 
Th eir bone marrow-derived precursors 
enter from the bloodstream as immature 
DCs. Th ese migrate through tissues, col-
lect antigens, and sense ‘danger’ signals 
(pathogen-derived molecular patterns, 
tissue damage, local inflammation). 
Such signals induce DC maturation, 
which results in the loss of phagocytic 
activity and expression of co-stimula-
tory molecules and enhances migration 
to draining lymph nodes, where naive 
T cells await activation. Activated T cells 
leave the lymph nodes in search of the 
antigen source — for example, infectious 
pathogens which they can combat either 
directly or indirectly by stimulating other 
immune eff ectors, such as macrophages. 
In the absence of pathogens, DCs will 
remain immature and fail to upregulate 
co-stimulatory molecules. Autoantigens 
carried by such immature DCs will toler-
ize autoreactive T cells. In this way, DCs 
also maintain peripheral self-tolerance. 
Whether these fundamental principles 
that have been demonstrated for DCs 
in the skin, intestine, pancreatic islets, 
lungs, or liver apply also to renal DCs is 
mostly unknown.
Our lack of knowledge about renal 
DCs is partially due to technical diffi  cul-
ties in detecting and isolating these frag-
ile cells from the kidney. Th us, the fi rst 
convincing evidence for their existence 
was provided not earlier than in 1994, 
when Kaissling and Le Hir observed by 
electron microscopy numerous tubu-
lointerstitial cells with DC morphol-
ogy.2 In the same year, Austyn, Roake, 
and colleagues reported functional 
major histocompatibility complex 
class II+ expression by these cells and their 
ability to induce T-cell allo-activation.3 
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